Pfizer signs giant cancer drug deal with Chinese biotech
Pfizer on Tuesday announced a cancer drug licensing deal with Chinese biotech 3SBio that includes a $1.25 billion upfront payment and $4.8 billion in potential earnouts. Pfizer also plans to invest $100 million for an equity stake.
Why it matters: This highlights how globalization is still finding a way in pharma, despite trade tensions that threaten to fracture the market.
There even were worries expressed during a recent Axios Pro Deals event that there eventually could be U.S. tariffs on Chinese drug IP.
Zoom in: Pfizer would get ex-China rights to a bispecific drug candidate for treating colorectal, ovarian and non-small cell lung cancers. It's expected to begin Phase III trials this year in China.
Go deeper, via Fierce Biotech: "Interest in PD-1/L1xVEGF bispecifics has been high since Summit and Akeso's ivonescimab beat Merck's megablockbuster Keytruda in a head-to-head trial. Since then, Merck has paid $588 million to join the race and BioNTech has handed over $800 million to secure full rights to a candidate it previously picked up through an ex-China deal."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
40 minutes ago
- Yahoo
11.4% dividend yield and 17 years of growth — is there passive income potential in a lesser-known FTSE stock?
When searching for passive income stocks, it's easy to be swayed by high dividend yields. The higher the yield, the more the income, right? Technically, yes. However, relying solely on the yield can end in disaster if the company lacks a reliable dividend track record. That's why this lesser-known UK stock with an 11.4% yield and 17 years of uninterrupted dividend growth caught my attention. But is there more to the story? Henderson Far East Income's (LSE: HFEL) a British investment trust that isn't on the FTSE 100 or FTSE 250 yet. For that reason, it's flown under my radar for some time. As the name suggests, it invests in major East Asian companies such as TSMC, China Construction Bank and Alibaba. It invests mostly in financial services and technology, with 20% of assets in China, 15% in Hong Kong, 12% in South Korea and the rest spread across the region. The trust's commitment to delivering a high and growing income's evident in its consistent dividend policy, with payments fully covered by revenues. Recently, its revenue reserves have reached an all-time high, providing a cushion for future payouts. This reliability's particularly attractive for investors seeking a steady income. While HFEL's primary focus is income, it also aims for capital growth. In the year to October 2024, the trust achieved a 17.4% net asset value (NAV) return — a notable improvement on previous years. This is attributed to a strategic portfolio shift towards structural growth opportunities in markets like India and Indonesia, and reduced exposure to China. The trust's diversified approach across various sectors and countries positions it to capitalise on Asia's evolving economic landscape. The trust's impressive dividend policy is certainly reassuring, but there are still some areas of concern. For instance, its heavy focus on the Asia-Pacific region exposes it to geopolitical tensions, currency fluctuations and regulatory changes. In the past, economic challenges in China have impacted performance and may well do so again. Additionally, the use of gearing amplifies both potential gains and losses, adding another layer of risk. At times, it can run at a high premium to NAV, which can affect the long-term value of the investment. Unfortunately, the fund's price performance hasn't been spectacular, which weighs on total returns. Over the past 10 years, the share price is down 25%. However, when adjusting for dividends, it's returned around 42% to shareholders — equating to a rather weak annualised return of 3.57%. After being in a steady decline since late 2017, the price is now near a 15-year low. That means it could be a great entry point if Asian markets recover in the coming years. However, if it continues the same performance over the next decade, it's likely to return less than a simple FTSE 100 index tracker. Whether or not an investor wants to consider it would be based on their expectations in that regard. Yes, it may pan out to be a good opportunity, but for now, I'm keeping my sights set on dividend stocks with higher overall returns. The post 11.4% dividend yield and 17 years of growth — is there passive income potential in a lesser-known FTSE stock? appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool Mark Hartley has no position in any of the shares mentioned. The Motley Fool UK has recommended Taiwan Semiconductor Manufacturing. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
42 minutes ago
- Yahoo
China says it may speed up rare earths application approvals from EU
SHANGHAI (Reuters) - China said on Saturday it was willing to accelerate the examination and approval of rare earth exports to European Union firms. A statement on the commerce ministry's website also said it plans to issue a final announcement on its trade investigation of brandy imports from the EU on July 5, saying that the two sides were discussing a price pledge. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
an hour ago
- Yahoo
UBS Lifts Kingsoft Cloud Holdings Limited (KC) to $14 Amid AI Growth
On Thursday, UBS analysts raised the price target for Kingsoft Cloud Holdings Limited (NASDAQ:KC) while maintaining a "Buy" rating. This confidence is attributed to the company's position as a pure-play cloud vendor with huge AI potential, anticipated to increase to over 40% by 2027, in contrast to 17% of total revenue in 2024. An executive standing in front of their headquarters building, proudly symbolizing the company's achievements. A fascinating development is the anticipated rebound in the company's public cloud segment, which is projected to achieve a 20% revenue compound annual growth rate (CAGR) by 2027. From the climbing demand for AI-powered cloud solutions, greater contributions from Xiaomi's ecosystem, and sustained growth in external clients, the reasons that explain this surge are many. Analysts also anticipate that Kingsoft Cloud Holdings Limited's (NASDAQ:KC) non-GAAP operating margin will improve, with narrow losses expected until achieving profitability by 2027. This strengthened standing is driven by higher revenue dependence on AI and enhanced cost efficiency from scaling operations. Indeed, it's AI that is backing the analysts' bullish stance. Kingsoft Cloud Holdings Limited (NASDAQ:KC) is a Chinese cloud service provider that offers cloud solutions, research and development services, enterprise digital solutions, and related services. Founded in 2012, the company aims to become clients' trusted partners and capitalize on digitalization. While we acknowledge the potential of KC as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
